NRSN

NeuroSense Therapeutics Ltd. (NRSN) | Rumor.io

NeuroSense Therapeutics

NRSN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,571

Bullish sentiment (50-day avg)65%

Price to earnings ratio-11.6

Market capitalization9.7M

Earnings per share-8.8

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-11.1M

Social

What share of all stock conversation is about NRSN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 28

The company, NeuroSense Therapeutics Ltd., plans to adopt an AI-driven, shorter, and smaller trial design (a reduced pivotal PARAGON design) and is exploring with the FDA whether existing data suffice for an Accelerated Approval pathway.
The company is actively seeking non-dilutive funding sources, strategic partnerships, or M&A transactions to ensure its continued viability and has successfully completed the Pre-NDS process with Health Canada.
The company has delayed the PARAGON trial to Q3 2027, and there is no update on the MVLS notification, with a deadline set for tomorrow, raising concerns about the company's plans and potential dilution.

Generated by AI

Sentiment

Of the messages about NRSN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	66.67%	66.15% +4.15	61.54% -22.9
Bearish	100%	33.33%	33.85% -4.15	38.46% +22.9

Bullish· Sep 10

The company has a strong cash balance, which suggests it has the funds to pursue its goals.
A potential partnership deal is expected to bring in significant funding for a phase 3 trial, which could be a major catalyst for the stock.
The company has a promising drug in development, with potential to treat ALS and other diseases, and has a solid scientific foundation that could lead to significant returns.

Bearish· Dec 8

The investor meeting was described as "appalling" and "amateurish," with the company providing no significant updates or compelling reasons to invest.
The company's financial situation is uncertain, with the possibility of dilution and a lack of urgency in securing funding, leaving them with less than $1 million in cash.
The presentation was criticized for being unprofessional and lacking in substance, leading to a significant drop in the stock price and a reduction in investment position by some investors.

Generated by AI

Topics

Of the messages about NRSN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	25%	45.45%	20.57%	64.08%
Technical Analysis	0%	27.27%	2.13%	7.56%
Analysts	0%	0%	37.59%	15.76%
Controversies	75%	27.27%	2.13%	1.26%
Macro	0%	0%	37.59%	11.13%
Earnings	0%	0%	0%	0.21%

Announcements· Dec 5

NeuroSense Therapeutics Ltd. ($NRSN) announced positive results from its Phase 2b ALS trial, achieving primary safety and tolerability, as well as secondary clinical efficacy endpoints.
The trial's results support moving forward to a Phase 3 pivotal trial, with the potential to slow down ALS progression and preserve quality of life for patients.
NeuroSense's CEO, Alon Ben Noon, stated that the company looks forward to meeting with the FDA to determine the best path forward and to advancing discussions with strategic partners to advance the PrimeC treatment for ALS.

Technical Analysis· Jan 19

$NRSN has been shorted successfully after gapping up, with the author noting the importance of volume, filings, and risk management.
The stock has formed a bull flag and a bullish pennant on the 5-minute chart, indicating a potential continuation of the upward trend.
The author is targeting $2.85 and $3.30-$3.35 for $NRSN, with support levels at $2.20 and $2.05.

Generated by AI

Community

Of the messages about NRSN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60%	66.67%	50.96%	62.53%
Newcomers	40%	33.33%	49.04%	37.47%

Regulars· Sep 28

The company, NeuroSense Therapeutics Ltd., is exploring a reduced pivotal PARAGON design with the FDA to potentially avoid massive costs and is seeking non-dilutive funding sources or strategic partnerships to ensure its continued viability.
The company plans to submit a formal drug approval application to Health Canada in December 2026 and is actively pursuing a focused strategy to bridge the gap between promising science and a cash shortage.
The company's management is being criticized for allegedly delaying the PARAGON trial and not providing clear updates on the company's progress, with some investors calling for the management to be replaced and others expressing concerns about the company's potential delisting from trading.

Newcomers· Dec 6

The newcomer is asking about a specific entry on $NRSN, inquiring why it was chosen when the stock spiked.
There is a price update for NeuroSense Therapeutics Ltd. ($NRSN) showing a significant decrease in stock price.
The newcomer is highlighting the decline in NeuroSense Therapeutics Ltd. ($NRSN) stock price, comparing it to Immunoprecise Antibodies Ltd. ($IPA) with a similar drop.

Generated by AI

News

NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

20d agotheglobeandmail.com

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

21d agoThe Globe and Mail

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

29d agoMorningstar

NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval

29d agoBenzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session

1mo agoBenzinga

NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts

Detailed price information for Neurosense Therapeutics Ltd (NRSN-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about NRSN also mention

#	Name	Attention
1	Kidpik Corp.PIK	0%new
2	ALLG - Allego N.V.	——
3	Comera Life Sciences Holdings Inc.CMRA	0%0
4	IGMS - IGM Biosciences, Inc.	——
5	Society Pass IncorporatedSOPA	0%0
6	Longeveron Inc. Class A Common StockLGVN	0%0
7	Lixte Biotechnology Holdings Inc.LIXT	0%new
8	Biofrontera Inc.BFRI	0%0
9	TCBP - TC Biopharm (Holdings) Plc	——
10	Nuvectis Pharma, Inc.NVCT	0%0

NeuroSense Therapeutics Ltd.

Healthcare
Biotechnology

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is an oral combination therapy designed for amyotrophic lateral sclerosis (ALS), while its broader pipeline includes research programs for Alzheimer’s disease and Parkinson’s disease. The company develops targeted therapeutic approaches intended to address complex neurological conditions with significant unmet medical need. NeuroSense Therapeutics Ltd. operates in the global biopharmaceutical market, where it contributes to the advancement of novel drug candidates through clinical and preclinical development. Based in Herzliya, Israel, the company is positioned within the specialized field of neuroscience-focused drug discovery and development.

Website

Location

Building B

Herzliya, 4672562

Israel

Social

What share of all stock conversation is about NRSN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 28

The company, NeuroSense Therapeutics Ltd., plans to adopt an AI-driven, shorter, and smaller trial design (a reduced pivotal PARAGON design) and is exploring with the FDA whether existing data suffice for an Accelerated Approval pathway.
The company is actively seeking non-dilutive funding sources, strategic partnerships, or M&A transactions to ensure its continued viability and has successfully completed the Pre-NDS process with Health Canada.
The company has delayed the PARAGON trial to Q3 2027, and there is no update on the MVLS notification, with a deadline set for tomorrow, raising concerns about the company's plans and potential dilution.

Generated by AI

Sentiment

Of the messages about NRSN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	66.67%	66.15% +4.15	61.54% -22.9
Bearish	100%	33.33%	33.85% -4.15	38.46% +22.9

Bullish· Sep 10

The company has a strong cash balance, which suggests it has the funds to pursue its goals.
A potential partnership deal is expected to bring in significant funding for a phase 3 trial, which could be a major catalyst for the stock.
The company has a promising drug in development, with potential to treat ALS and other diseases, and has a solid scientific foundation that could lead to significant returns.

Bearish· Dec 8

The investor meeting was described as "appalling" and "amateurish," with the company providing no significant updates or compelling reasons to invest.
The company's financial situation is uncertain, with the possibility of dilution and a lack of urgency in securing funding, leaving them with less than $1 million in cash.
The presentation was criticized for being unprofessional and lacking in substance, leading to a significant drop in the stock price and a reduction in investment position by some investors.

Generated by AI

Topics

Of the messages about NRSN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	25%	45.45%	20.57%	64.08%
Technical Analysis	0%	27.27%	2.13%	7.56%
Analysts	0%	0%	37.59%	15.76%
Controversies	75%	27.27%	2.13%	1.26%
Macro	0%	0%	37.59%	11.13%
Earnings	0%	0%	0%	0.21%

Announcements· Dec 5

NeuroSense Therapeutics Ltd. ($NRSN) announced positive results from its Phase 2b ALS trial, achieving primary safety and tolerability, as well as secondary clinical efficacy endpoints.
The trial's results support moving forward to a Phase 3 pivotal trial, with the potential to slow down ALS progression and preserve quality of life for patients.
NeuroSense's CEO, Alon Ben Noon, stated that the company looks forward to meeting with the FDA to determine the best path forward and to advancing discussions with strategic partners to advance the PrimeC treatment for ALS.

Technical Analysis· Jan 19

$NRSN has been shorted successfully after gapping up, with the author noting the importance of volume, filings, and risk management.
The stock has formed a bull flag and a bullish pennant on the 5-minute chart, indicating a potential continuation of the upward trend.
The author is targeting $2.85 and $3.30-$3.35 for $NRSN, with support levels at $2.20 and $2.05.

Generated by AI

Community

Of the messages about NRSN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60%	66.67%	50.96%	62.53%
Newcomers	40%	33.33%	49.04%	37.47%

Regulars· Sep 28

The company, NeuroSense Therapeutics Ltd., is exploring a reduced pivotal PARAGON design with the FDA to potentially avoid massive costs and is seeking non-dilutive funding sources or strategic partnerships to ensure its continued viability.
The company plans to submit a formal drug approval application to Health Canada in December 2026 and is actively pursuing a focused strategy to bridge the gap between promising science and a cash shortage.
The company's management is being criticized for allegedly delaying the PARAGON trial and not providing clear updates on the company's progress, with some investors calling for the management to be replaced and others expressing concerns about the company's potential delisting from trading.

Newcomers· Dec 6

The newcomer is asking about a specific entry on $NRSN, inquiring why it was chosen when the stock spiked.
There is a price update for NeuroSense Therapeutics Ltd. ($NRSN) showing a significant decrease in stock price.
The newcomer is highlighting the decline in NeuroSense Therapeutics Ltd. ($NRSN) stock price, comparing it to Immunoprecise Antibodies Ltd. ($IPA) with a similar drop.

Generated by AI

NeuroSense Therapeutics

Social

Sep 28

Bullish· Sep 10

Bearish· Dec 8

Announcements· Dec 5

Technical Analysis· Jan 19

Regulars· Sep 28

Newcomers· Dec 6

NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq

Wall Street Analysts Are Bullish on Top Healthcare Picks

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval

12 Health Care Stocks Moving In Tuesday's After-Market Session

NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts

Also Discussed

NeuroSense Therapeutics Ltd.

Company Information

Location

NeuroSense Therapeutics to Enact 1-for-20 Reverse Share Split on Nasdaq

Wall Street Analysts Are Bullish on Top Healthcare Picks

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval

12 Health Care Stocks Moving In Tuesday's After-Market Session

NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance Efforts

Also Discussed

Social

Sep 28

Bullish· Sep 10

Bearish· Dec 8

Announcements· Dec 5

Technical Analysis· Jan 19

Regulars· Sep 28

Newcomers· Dec 6